AIDS Treatment News logo      

July 21, 2010

Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Program for Investigational Once-Daily HIV Integrase Inhibitor

AlphaTrade Finance: "Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.  

"This decision is based on promising results from two Phase IIb trials, SPRING-1 and VIKING, which are being presented this week at the XVIII International AIDS Conference in Vienna, Austria (Abstract Numbers THLBB205 & MOAB0105). These trials explored the efficacy of '572 in treatment-naive HIV subjects as well as in treatment-experienced subjects resistant to raltegravir. Further study in Phase III is necessary to determine conclusively the safety, efficacy and resistance profile of '572."

0 comments: